Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Status:
Recruiting
Trial end date:
2023-10-24
Target enrollment:
Participant gender:
Summary
This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and
recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when combined
with the CDK4/6 inhibitor palbociclib.